Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.11.20 - elongation factor 2 kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.
Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.
Regulation of elongation factor-2 kinase by pH.
Acquired Immunodeficiency Syndrome
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.
Adenocarcinoma
eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
Adenocarcinoma of Lung
Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress.
Alzheimer Disease
Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice.
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.
Anemia
Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias.
The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.
Atherosclerosis
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation.
beta-Thalassemia
Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.
Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia.
The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.
Brain Ischemia
Eukaryotic initiation factor 2alpha kinase and phosphatase activity during postischemic brain reperfusion.
Oxidative injury to the endoplasmic reticulum in mouse brains after transient focal ischemia.
Brain Neoplasms
Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
Breast Neoplasms
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.
Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer.
Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.
Design, synthesis and structure-activity relationship of a focused library of ?-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.
eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
High-Throughput Screens for eEF-2 Kinase.
Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.
Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact.
Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors.
Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer.
Carcinogenesis
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Elongation factor-2 kinase: its role in protein synthesis and autophagy.
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Carcinoma
eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.
Carcinoma, Hepatocellular
Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF ?TrCP-mediated eEF2K degradation.
Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.
Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
Carcinoma, Renal Cell
MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.
Cardiomegaly
Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.
Cardiovascular Diseases
Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.
Colonic Neoplasms
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Colorectal Neoplasms
Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.
The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells.
Cytomegalovirus Infections
Repression of eEF2K transcription by NF-?B tunes translation elongation to inflammation and dsDNA-sensing.
Diabetes Mellitus, Type 2
Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin.
elongation factor 2 kinase deficiency
Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.
Paradoxical Roles of Elongation Factor-2 Kinase in Stem Cell Survival.
Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses.
Encephalitis
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Encephalomyelitis
GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.
Encephalomyelitis, Autoimmune, Experimental
GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.
Epilepsy
eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures.
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Esophageal Squamous Cell Carcinoma
eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
Essential Hypertension
Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.
Fetal Growth Retardation
Intrauterine growth restriction inhibits expression of eukaryotic elongation factor 2 kinase, a regulator of protein translation.
Fibrosarcoma
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Glioblastoma
Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.
Elongation factor-2 kinase: its role in protein synthesis and autophagy.
Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.
Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells.
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Glioma
eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206.
eEF-2 kinase, another meddler in the "Yin and Yang" of Akt-mediated cell fate?
Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells.
Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.
High-Throughput Screens for eEF-2 Kinase.
Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.
Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression.
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.
Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.
Herpes Simplex
PKR-Dependent Autophagic Degradation of Herpes Simplex Virus Type 1.
Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway.
Hyperglycemia
Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin.
Hypertension
Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.
Eukaryotic elongation factor 2 kinase inhibitor, A484954 inhibits noradrenaline-induced acute increase of blood pressure in rats.
Eukaryotic elongation factor 2 kinase inhibitor, A484954 potentiates ?-adrenergic receptor agonist-induced acute decrease in diastolic blood pressure in rats.
Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling.
Eukaryotic elongation factor 2 kinase regulates the development of hypertension through oxidative stress-dependent vascular inflammation.
Expression and localization of calmodulin-related proteins in brain, heart and kidney from spontaneously hypertensive rats.
Hypertension, Pulmonary
Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension.
Infections
Human cytomegalovirus infection activates and regulates the unfolded protein response.
Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection.
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.
Influenza, Human
P58(IPK): a novel "CIHD" member of the host innate defense response against pathogenic virus infection.
P58: A Novel "CIHD" Member of the Host Innate Defense Response against Pathogenic Virus Infection.
Iron Deficiencies
Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.
Haem-regulated eIF2alpha kinase is necessary for adaptive gene expression in erythroid precursors under the stress of iron deficiency.
Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency.
The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.
Iron Overload
Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.
Ischemic Attack, Transient
Mechanisms underlying suppression of protein synthesis induced by transient focal cerebral ischemia in mouse brain.
Liver Neoplasms
Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
Lung Neoplasms
Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.
Eef2k is not required for fertility in male mice.
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact.
The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2.
Lymphatic Metastasis
eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
Malnutrition
Coping with stress: eIF2 kinases and translational control.
Medulloblastoma
Energy metabolism in neurodevelopment and medulloblastoma.
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Melanoma
Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.
Memory Disorders
Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice.
Nasopharyngeal Carcinoma
Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells.
Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.
Neoplasm Metastasis
eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Neoplasm, Residual
eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
Neoplasms
1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.
A conserved loop in the catalytic domain of eukaryotic elongation factor 2 kinase plays a key role in its substrate specificity.
A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors.
Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress.
Adaptation to starvation: translating a matter of life or death.
AMPK decreases ERK1/2 activity and cancer cell sensitivity to nutrition deprivation by mediating a positive feedback loop involving eEF2K.
Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening.
Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.
Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha kinase: down-regulated in epithelial ovarian cancers.
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
Detection of anti-elongation factor 2 kinase (calmodulin-dependent protein kinase III) antibodies in patients with systemic lupus erythematosus.
Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase.
Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.
Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.
eEF-2 kinase, another meddler in the "Yin and Yang" of Akt-mediated cell fate?
eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells.
eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.
eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
eEF2K: an atypical kinase target for cancer.
Elongation factor 2 kinase is regulated by proline hydroxylation and protects cells during hypoxia.
Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy.
Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.
Elongation factor-2 kinase regulates TG2/?1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Elongation factor-2 kinase: its role in protein synthesis and autophagy.
Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.
Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.
Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.
Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells.
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation?
Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.
Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase.
Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation.
Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.
Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression.
Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.
Minimum requirements for the function of eukaryotic translation initiation factor 2.
Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.
P-glycoprotein mediates resistance to histidine kinase inhibitors.
Paradoxical Roles of Elongation Factor-2 Kinase in Stem Cell Survival.
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.
Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli.
Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.
Regulation and roles of elongation factor 2 kinase.
Reversible covalent inhibition of eEF-2K by carbonitriles.
Roles of eEF-2 kinase in cancer.
Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.
Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways.
Stress-mediated translational control in cancer cells.
Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: Homology modeling, Molecular Docking and Molecular Dynamics Simulation.
Surviving metabolic stress: of mice (squirrels) and men.
Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo.
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer.
Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells.
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2.
Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review.
[Eukaryotic elongation factor 2 kinase and cancer].
Nervous System Diseases
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Neuroblastoma
Bicuculline regulated protein synthesis is dependent on Homer1 and promotes its interaction with eEF2K through mTORC1-dependent phosphorylation.
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Neurodegenerative Diseases
Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Ovarian Neoplasms
Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Pancreatic Neoplasms
Elongation factor-2 kinase regulates TG2/?1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
Parkinson Disease
Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity.
Prostatic Neoplasms
Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.
Protoporphyria, Erythropoietic
Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia.
Pulmonary Arterial Hypertension
Age-dependent increase in activity of eukaryotic elongation factor 2 kinase in mesenteric arteries from spontaneously hypertensive rats.
Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling.
Pulmonary Veno-Occlusive Disease
Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension.
Starvation
A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses.
Activation of GCN2 in macrophages promotes white adipose tissue browning and lipolysis under leucine deprivation.
Activation of Gcn2 in response to different stresses.
Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program.
Basal expression of the Aspergillus fumigatus transcriptional activator CpcA is sufficient to support pulmonary aspergillosis.
cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner.
eEF2K protects MYCN-amplified cells from starvation.
Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy.
Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.
Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.
Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.
Evidence that GCN1 and GCN20, translational regulators of GCN4, function on elongating ribosomes in activation of eIF2alpha kinase GCN2.
GCN1, a translational activator of GCN4 in Saccharomyces cerevisiae, is required for phosphorylation of eukaryotic translation initiation factor 2 by protein kinase GCN2.
IfkA, a presumptive eIF2 alpha kinase of Dictyostelium, is required for proper timing of aggregation and regulation of mound size.
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
L-arginine availability regulates T-lymphocyte cell-cycle progression.
L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression.
Mutations activating the yeast eIF-2 alpha kinase GCN2: isolation of alleles altering the domain related to histidyl-tRNA synthetases.
Regulation and roles of elongation factor 2 kinase.
Snf1 promotes eIF2{alpha} phosphorylation by activating Gcn2 and inhibiting phosphatases Glc7 and Sit4.
The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids.
The molecular aetiology of tRNA synthetase depletion: induction of a GCN4 amino acid starvation response despite homeostatic maintenance of charged tRNA levels.
The protein kinase Gcn2p mediates sodium toxicity in yeast.
The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif.
Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner.
Stomach Neoplasms
eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
Stomach Ulcer
Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection.
Triple Negative Breast Neoplasms
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
Cunning maneuver regulating chemotherapy resistance in triple-negative breast cancer by eEF2K and autophagy.
eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: Homology modeling, Molecular Docking and Molecular Dynamics Simulation.
Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Vesicular Stomatitis
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.
Virus Diseases
GCN2 has inhibitory effect on human immunodeficiency virus-1 protein synthesis and is cleaved upon viral infection.
Increased susceptibility to DNA virus infection in mice with a GCN2 mutation.
P58(IPK): a novel "CIHD" member of the host innate defense response against pathogenic virus infection.
P58: A Novel "CIHD" Member of the Host Innate Defense Response against Pathogenic Virus Infection.
Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway.
Tyrosine phosphorylation acts as a molecular switch to full-scale activation of the eIF2alpha} RNA-dependent protein kinase.